Needham & Co initiates coverage on Poniard Pharmaceuticals (Nasdaq: PARD) with a Buy. Price target $6.

Needham analyst ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE